HANS BIOMED (042520) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HANS BIOMED (042520) reported revenue of 89.8 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202589.8 billion KRW-25.9 billion KRW-32.1 billion KRW[source]
202481.1 billion KRW626 million KRW-7.8 billion KRW[source]
202378.0 billion KRW-4.2 billion KRW-24.1 billion KRW[source]
202274.5 billion KRW1.3 billion KRW4.9 billion KRW[source]
202159.1 billion KRW-19.8 billion KRW-22.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025106.6 billion KRW77.2 billion KRW29.4 billion KRW[source]
2024105.8 billion KRW44.8 billion KRW61.0 billion KRW[source]
2023109.5 billion KRW65.7 billion KRW43.8 billion KRW[source]
2022123.9 billion KRW77.8 billion KRW46.1 billion KRW[source]
2021122.5 billion KRW76.3 billion KRW46.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice